B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

References

• O’DellJRCecil Medicine23rd edPhiladelphia, PASaunders2007
   Google Scholar
• van der LubbePABreedveldFCTakPPSchantzAWoodyJMiltenburgAMTreatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4 +/CD45RA + cells in patients with rheumatoid arthritisJ Autoimmun199710187979080303
   PubMed Web of Science ®Google Scholar
• TanakaYTreatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseasesIntern Med200746161313131517704614
   PubMed Web of Science ®Google Scholar
• BayryJLacroix-DesmazesSKazatchkineMDKaveriSVMonoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of actionNat Clin Pract Rheumatol20073526227217471245
   PubMedGoogle Scholar
• ThompsonKMBorretzenMRandenIForreONatvigJBV-gene repertoire and hypermutation of rheumatoid factors produced in rheumatoid synovial inflammation and immunized healthy donorsAnn N Y Acad Sci19957644404497486562
   PubMed Web of Science ®Google Scholar
• Rantapaa-DahlqvistSde JongBABerglinEAntibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis Rheum2003482741274914558078
   PubMed Web of Science ®Google Scholar
• BerglinEPadyukovLSundinUA combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritisArthritis Res Ther20046R303R30815225365
   PubMed Web of Science ®Google Scholar
• NishimuraKSugiyamaDKogataYMeta-analysis: Diagnostic accuracy of anti-cyclic cintrullinated peptide antibody and rheumatoid factor for rheumatoid arthritisAnn Intern Med200714679780817548411
   PubMed Web of Science ®Google Scholar
• HigashidaJWunTSchmidtSNaguwaSMTuscanoJMSafety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatmentJ Rheumatol200532112109211516265687
   PubMed Web of Science ®Google Scholar
• EdwardsJCSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med2004350252572258115201414
   PubMed Web of Science ®Google Scholar
• DavidsonA DBAutoimmune diseasesN Engl J Med2001345534035011484692
   PubMed Web of Science ®Google Scholar
• HudsonBGTryggvasonKSundaramoorthyMNeilsonEGAlport’s syndrome, Goodpasture’s syndrome, and type IV collagenN Engl J Med2003348252543255612815141
   PubMed Web of Science ®Google Scholar
• RichmanDPAgiusMATreatment of autoimmune myasthenia gravisNeurology200361121652166114694025
   PubMed Web of Science ®Google Scholar
• RavetchJVBollandSIgG Fc receptorsAnnu Rev Immunol20011927529011244038
   PubMed Web of Science ®Google Scholar
• BinstadtBAGehaRSBonillaFAIgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapyJ Allergy Clin Immunol2003111469770312704346
   PubMed Web of Science ®Google Scholar
• HolersVMThe complement system as a therapeutic target in autoimmunityClin Immunol2003107314015112804527
   PubMed Web of Science ®Google Scholar
• ChanOTHannumLGHabermanAMMadaioMPShlomchikMJA novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupusJ Exp Med1999189101639164810330443
   PubMed Web of Science ®Google Scholar
• ShlomchikMJMadaioMPNiDTrounsteinMHuszarDThe role of B cells in lpr/lpr-induced autoimmunityJ Exp Med19941804129513067931063
   PubMed Web of Science ®Google Scholar
• McMillanRAntiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopesJ Pediatr Hematol Oncol200325Suppl 1S57S6114668642
   PubMed Web of Science ®Google Scholar
• McMillanRLopez-DeeJLoftusJCAutoantibodies to alpha (IIb)beta(3) in patients with chronic immune thrombocytopenic purpura bind primarily to epitopes on alpha(IIb)Blood20019772171217211264188
   PubMed Web of Science ®Google Scholar
• SamuelssonATowersTLRavetchJVAnti-inflammatory activity of IVIG mediated through the inhibitory Fc receptorScience2001291550348448611161202
   PubMed Web of Science ®Google Scholar
• StasiRPaganoAStipaEAmadoriSRituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood200198495295711493438
   PubMed Web of Science ®Google Scholar
• SalehMNGutheilJMooreMA pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopeniaSemin Oncol2000276 Suppl 129910311226008
   PubMed Web of Science ®Google Scholar
• ZajaFVianelliNSperottoAB-cell compartment as the selective target for the treatment of immune thrombocytopeniasHaematologica200388553854612745273
   PubMed Web of Science ®Google Scholar
• CooperNStasiRCunningham-RundlesSThe efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBr J Haematol2004125223223915059147
   PubMed Web of Science ®Google Scholar
• RileyJKSliwkowskiMXCD20: a gene in search of a functionSemin Oncol2000276 Suppl 12172411225995
   PubMed Web of Science ®Google Scholar
• McLaughlinPGrillo-LopezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBriereJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• BreedveldFAgarwalSYinMRituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical responseJ Clin Pharmacol20074791119112817766699
   PubMed Web of Science ®Google Scholar
• NgCMBrunoRCombsDDaviesBPopulation pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trialJ Clin Pharmacol200545779280115951469
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRFilipowicz-SosnowskaAThe efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialArthritis Rheum20065451390140016649186
   PubMed Web of Science ®Google Scholar
• MeasePJRevickiDASzechinskiJImproved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) TrialJ Rheumatol2008351203018050385
   PubMed Web of Science ®Google Scholar
• MathiasSDColwellHHMillerDPMorelandLWBuattiMWankeLHealth-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placeboClin Ther200022112813910688396
   PubMed Web of Science ®Google Scholar
• HeibergMSNordvagBYMikkelsenKThe comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter studyArthritis Rheum20055282506251216052584
   PubMed Web of Science ®Google Scholar
• KeystoneECKavanaughAFSharpJTRadiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trialArthritis Rheum20045051400141115146409
   PubMed Web of Science ®Google Scholar
• KaplanRMGroesslEJSenguptaNSieberWJGaniatsTGComparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritisMed Care2005431798715626937
   PubMed Web of Science ®Google Scholar
• MainiRNBreedveldFCKaldenJRSustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexateArthritis Rheum20045041051106515077287
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum20065492793280616947627
   PubMed Web of Science ®Google Scholar
• StrandVBalbir-GurmanAPavelkaKSustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 yearsRheumatology (Oxford)200645121505151317062648
   PubMed Web of Science ®Google Scholar
• KeystoneEEmeryPPeterfyCGRituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesAnn Rheum Dis20096821622118388156
   PubMed Web of Science ®Google Scholar
• ThurlingsRMVosKWijbrandtsCASynovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnn Rheum Dis20086791792517965121
   PubMed Web of Science ®Google Scholar
• KavanaughARosengrenSLeeSJAssessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1:clinical and synovial biomarker resultsAnn Rheum Dis20086740240817644541
   PubMed Web of Science ®Google Scholar
• VosKThurlingsRMWijbrandtsCAEarly effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritisArthritis Rheum200756377277817328049
   PubMed Web of Science ®Google Scholar
• RollPDornerTTonyHAnti-CD20 therapy in patients with rheumatoid arthritisArthritis Rheum20085861566157518512772
   PubMed Web of Science ®Google Scholar
• DassSRawstronAVitalEHighly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisArthritis Rheum200858102993299918821683
   PubMed Web of Science ®Google Scholar
• ThurlingsRMVosKGerlagDDisease activity-guided rituximab therapy in rheumatoid arthritisArthritis Rheum200858123657366419035505
   PubMed Web of Science ®Google Scholar